ProQR Therapeutics NV (NASDAQ:PRQR)‘s stock had its “outperform” rating restated by investment analysts at Leerink Swann in a research report issued to clients and investors on Friday. They presently have a $14.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s target price points to a potential upside of 120.47% from the company’s current price.
A number of other research firms have also recently weighed in on PRQR. Janney Montgomery Scott assumed coverage on shares of ProQR Therapeutics NV in a research note on Wednesday, September 28th. They set a “neutral” rating and a $7.00 target price on the stock. Zacks Investment Research raised shares of ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research note on Friday, September 23rd. JMP Securities reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Finally, Chardan Capital assumed coverage on shares of ProQR Therapeutics NV in a research note on Monday, June 20th. They set a “neutral” rating and a $4.50 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ProQR Therapeutics NV presently has an average rating of “Buy” and a consensus price target of $14.13.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.35 on Friday. ProQR Therapeutics NV has a 52 week low of $3.48 and a 52 week high of $16.23. The company’s 50-day moving average price is $6.44 and its 200 day moving average price is $5.44. The firm’s market cap is $148.25 million.
ProQR Therapeutics NV (NASDAQ:PRQR) last posted its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. On average, equities analysts anticipate that ProQR Therapeutics NV will post ($2.09) earnings per share for the current year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Sabby Management LLC raised its stake in ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned about 0.64% of ProQR Therapeutics NV worth $732,000 as of its most recent SEC filing. Institutional investors and hedge funds own 39.21% of the company’s stock.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.